Citations

Clear

1053 citation(s) found for "Andre, F".

β-Catenin Preserves the Stem State of Murine Bone Marrow Stromal Cells Through Activation of EZH2
Sen, Buer , Paradise, Christopher R. , Sankaran, Jeyantt Srinivas , Styner, Maya , Meyer, Mark B. , Dudakovic, Amel , Wijnen, André J. van , Rubin, Janet , Styner, Maya , Meyer, Mark , Rubin, Janet , van Wijnen, Andre J , van Wijnen, Andre J , Xie, Zhihui , Uzer, Gunes

Mayo Clinic

Journal of Bone and Mineral Research | February 5, 2020 | Volume: 35 | Issue: 6 | Pages: 1149-1162

10.1002/jbmr.3975 | PMID 32022326 Get It

ABSTRACT During bone marrow stromal cell (BMSC) differentiation, both Wnt signaling and the development of a rigid cytoskeleton promote commitment to the osteoblastic over adipogenic lineage. β-catenin plays a critical role in the Wnt signaling pathway to facilitate downstream effects on gene expression. We show that β-catenin was additive with cytoskeletal signals to prevent adipogenesis, and β-catenin knockdown promoted adipogenesis even when the actin cytoskeleton was depolymerized. β-catenin also prevented osteoblast commitment in a cytoskeletal-independent manner, with β-catenin knockdown enhancing lineage commitment. Chromatin immunoprecipitation (ChIP)-sequencing demonstrated binding of β-catenin to the promoter of enhancer of zeste homolog 2 (EZH2), a key component of the polycomb repressive complex 2 (PRC2) complex that catalyzes histone methylation. Knockdown of β-catenin reduced EZH2 protein levels and decreased methylated histone 3 (H3K27me3) at osteogenic loci. Further, when EZH2 was inhibited, β-catenin's anti-differentiation effects were lost. These results indicate that regulating EZH2 activity is key to β-catenin's effects on BMSCs to preserve multipotentiality. © 2020 American Society for Bone and Mineral Research.
Glycogen synthase kinase-3 beta (GSK-3β) blockade with 9-ing-41 in gastrointestinal cancers: The 1801 phase Ib/II study.
Safran, Howard , Dhawan, Mallika , Souza, André Luiz de , Powell, Steven , Billadeau, Daniel D. , Carneiro, Benedito A. , Cavalcante, Ludimila , Giles, Francis Joseph , Münster, Pamela N.

Mayo Clinic

Journal of Clinical Oncology | February 4, 2020 | Volume: 38 | Issue: 4_suppl | Pages: 827-827

10.1200/jco.2020.38.4_suppl.827 Get It

827 Background: 9-ING-41 is a selective GSK-3β inhibitor with significant pre-clinical antitumor activity in a broad spectrum of malignancies as a single agent and in combination with cytotoxic agents. GSK-3β is a serine/threonine kinase whose overexpression is associated with advanced stage, aggressive tumor growth, and chemotherapy resistance. We report the preliminary results of patients (pts) with gastrointestinal (GI) malignancies. Methods: Phase 1b/2 study evaluating safety and efficacy of 9-ING-41 as monotherapy and combination therapy in pts with refractory cancers. 9-ING-41 is administered intravenously twice-weekly as a single agent (21-day-cycle) or combined with chemotherapy agents, including gemcitabine (GEM), nab-paclitaxel + GEM, carboplatin, or paclitaxel. Study parts 1 and 2 evaluate the safety, describe dose-limiting toxicities (DLTs), determine the maximum tolerated dose and the recommended phase 2 study dose (RP2D) for 9-ING-41 as monotherapy (Part 1) and as combination therapy (Part 2). Part 3 (Simon 2-Stage Phase 2) assess clinical benefit in pts treated with 9-ING-41-based combinations at the RP2D established in Part 2. Response is assessed by RECIST 1.1 criteria in the evaluable lesions. Results: To date, the study accrued 63 pts. Five dose levels (1, 2, 3.3, 5 and 7 mg/kg) have been completed without DLTs. Part 2 of the study evaluating 9-ING-41-based chemotherapy combinations is ongoing. Five out of nine pts with pancreas cancer (PCa) enrolled had stable disease (SD) as the best response; 2 out of 9 pts had a 40-45% decline of CA 19-9. One pt completed 6 cycles with 9-ING-41, two pts completed 4 cycles with 9-ING-41/GEM. Two active pts are receiving 9-ING-41/GEM with SD after 3 and 4 cycles. Three out of four pts with adenocarcinoma of the appendix enrolled had SD as the best response; two pts in active treatment are receiving cycles 5 and 6. One out of 13 pts with colorectal cancer had SD. 9-ING-41-attributable AE to date are reversible grade 1 transient visual changes (color perception). Conclusions: 9-ING-41 is well-tolerated with encouraging SD among heavily pretreated pts with carcinoma of the pancreas and appendix. Clinical trial information: NCT03678883.
E‐cigarette or vaping product use–associated lung injury: What is the role of cytologic assessment?
Saqi, Anjali , Butt, Yasmeen M. , Doxtader, Erika , Heymann, Jonas J. , Larsen, Brandon T. , Moreira, André L. , Patel, Ami , Reynolds, Jordan , Sung, Simon , Crapanzano, John P. , Butt, Yasmeen, Doxtader, Erika , Heymann, Jonas J , Sung, Simon , Saqi, Anjali , Reynolds, Jordan P , Mukhopadhyay, Sanjay

Mayo Clinic

Cancer Cytopathology | January 27, 2020 | Volume: 128 | Issue: 6 | Pages: 371-380

10.1002/cncy.22237 | PMID 31985892 Get It

Greater than 2000 cases of vaping‐associated pulmonary injury and 39 deaths reported in the United States have heightened public awareness and assumed major public health significance over recent months. Currently, knowledge of the effects of various vaping agents on the respiratory tract is in its infancy. Additional understanding of the agents implicated in these lung injuries as well as a correlation between bronchoalveolar lavage and lung biopsy samples is required.
Phenotypic, Transcriptional, and Functional Analysis of Liver Mesenchymal Stromal Cells and Their Immunomodulatory Properties
Taner, Timuçin , Abrol, Nitin , Park, Walter D. , Hansen, Michael J. , Gustafson, Michael P. , Lerman, Lilach O. , Wijnen, André J. van , Dietz, Allan B. , Stegall, Mark D. , van Wijnen, Andre J , Dietz, Allan B , Stegall, Mark D , Park, Walter , Gores, Gregory J.

Mayo Clinic

Liver Transplantation | January 17, 2020 | Volume: 26 | Issue: 4 | Pages: 549-563

10.1002/lt.25718 | PMID 31950576 Get It

The liver is an immunologically active organ with a tolerogenic microenvironment at a quiescent state. The immunoregulatory properties of the liver appear to be retained after transplantation because liver allografts can reduce alloresponses against other organs that are simultaneously transplanted. Mechanisms of this phenomenon remain unknown. Given the known immunomodulatory properties of mesenchymal stromal cells (MSCs), we hypothesized that liver mesenchymal stromal cells (L‐MSCs) are superior immunomodulators and contribute to liver‐mediated tolerance. L‐MSCs, generated from human liver allograft biopsies, were compared with adipose mesenchymal stromal cells (A‐MSCs) and bone marrow mesenchymal stromal cells (BM‐MSCs). Trilineage differentiation of L‐MSCs was confirmed by immunohistochemistry. Comparative phenotypic analyses were done by flow cytometry and transcriptome analyses by RNA sequencing in unaltered cell cultures. The in vitro functional analyses were performed using alloreactive T cell proliferation assays. The transcriptome analysis showed that the L‐MSCs are different than the A‐MSCs and BM‐MSCs, with significant enrichment of genes and gene sets associated with immunoregulation. Compared with the others, L‐MSCs were found to express higher cell surface levels of several select immunomodulatory molecules. L‐MSCs (versus A‐MSCs/BM‐MSCs) inhibited alloreactive T cell proliferation (22.7% versus 56.4%/58.7%, respectively; P < 0.05) and reduced the frequency of interferon ɤ–producing T cells better than other MSCs (52.8% versus 94.4%/155.4%; P < 0.05). The antiproliferative impact of L‐MSCs was not dependent on cell‐to‐cell contact, could be reversed incompletely by blocking programmed death ligand 1, and required a higher concentration of the competitive inhibitor of indoleamine 2,3‐dioxygenase for complete reversal. In conclusion, L‐MSCs appear to be uniquely well‐equipped immunomodulatory cells, and they are more potent than A‐MSCs and BM‐MSCs in that capacity, which suggests that they may contribute to liver‐induced systemic tolerance.
Surveillance for HCC After Liver Transplantation: Increased Monitoring May Yield Aggressive Treatment Options and Improved Postrecurrence Survival
Lee, David D. , Mehta, Neil , Gorgen, Andre , Musto, Kaitlyn R., Hajda, Hana, Yao, Francis Y. , Hodge, David O. , Carter, Rickey E. , Harnois, Denise M. , Lee, David D , Carter, Rickey E , Sapisochín, Gonzalo

Mayo Clinic

Transplantation | January 16, 2020 | Volume: 104 | Issue: 10 | Pages: 2105-2112

10.1097/tp.0000000000003117 | PMID 31972705 Get It

Background. Currently, no surveillance guidelines for hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) exist. In this retrospective, multicenter study, we have investigated the role of surveillance imaging on postrecurrence outcomes. Methods. Patients with recurrent HCC after LT from 2002 to 2016 were reviewed from 3 transplant centers (University of California San Francisco, Mayo Clinic Florida, and University of Toronto). For this study, we proposed the term cumulative exposure to surveillance (CETS) as a way to define the cumulative sum of all the protected intervals that each surveillance test provides. In our analysis, CETS has been treated as a continuous variable in months. Results. Two hundred twenty-three patients from 3 centers had recurrent HCC post-LT. The median follow-up was 31.3 months, and median time to recurrence was 13.3 months. Increasing CETS was associated with improved postrecurrence survival (hazard ratio, 0.94; P < 0.01) as was treatment of recurrence with resection or ablation (hazard ratio, 0.31; P < 0.001). An receiver operating characteristic curve (area under the curve, 0.64) for CETS covariate showed that 252 days of coverage (or 3 surveillance scans) within the first 24 months provided the highest probability for aggressive postrecurrence treatment. Conclusions. In this review of 223 patients with post-LT HCC recurrence, we found that increasing CETS does lead to improved postrecurrence survival as well as a higher probability for aggressive recurrence treatment. We found that 252 days of monitoring (ie, 3 surveillance scans) in the first 24 months was associated with the ability to offer potentially curative treatment.
Randomized Controlled Trial of Mobile Closed-Loop Control
Kovatchev, Boris , Anderson, Stacey M. , Raghinaru, Dan, Kudva, Yogish C. , Laffel, Lori M. , Pinsker, Jordan E. , Buckingham, Bruce A. , Doyle, Francis J. , Brown, Sue A. , Church, Mei Mei , Dadlani, Vikash, Dassau, Eyal , Ekhlaspour, Laya , Forlenza, Gregory P. , Isganaitis, Elvira , Lam, David W. , Lum, John W. , Group, iDCL Study, Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Schultz, Alan , Kim, Kenny, Church, Mei Mei, André, Camille , Lam, David W., O’Malley, Grenye , Levister, Camilla, Ogyaadu, Selassie, Simha, Vinaya , McCrady-Spitzer, Shelly , Reid, Corey, Jost, Emily , Berget, Cari , Towers, Lindsey, Buckingham, Bruce, Ekhlaspour, Laya, Hsu, Liana, Loebner, Sarah E., Doyle, Francis J., Campos, Tiffany, Passman, Samantha, Murphy, Carlos, Patibandla, Nandan, Kollman, Craig, Pinsker, Jordan E , Doyle, Francis J , Dassau, Eyal , Ekhlaspour, Laya , Forlenza, Gregory P , Lum, John , Kovatchev, Boris , Buckingham, Bruce , Levy, Carol J. , Wadwa, R Paul , Beck, Roy W. , Group, iDCL Study, Oliveri, Mary Clancy , Church, Mei Mei, Lam, David W., Messer, Laurel H , Buckingham, Bruce, Ekhlaspour, Laya, Doyle, Francis J., Kollman, Craig

Mayo Clinic

Diabetes Care | January 15, 2020 | Volume: 43 | Issue: 3 | Pages: 607-615

10.2337/dc19-1310 | PMID 31937608 Get It

OBJECTIVE Assess the efficacy of inControl AP, a mobile closed-loop control (CLC) system. RESEARCH DESIGN AND METHODS This protocol, NCT02985866, is a 3-month parallel-group, multicenter, randomized unblinded trial designed to compare mobile CLC with sensor-augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least 1 year, use of insulin pumps for at least 6 months, age ≥14 years, and baseline HbA1c &lt;10.5% (91 mmol/mol). The study was designed to assess two coprimary outcomes: superiority of CLC over SAP in continuous glucose monitor (CGM)–measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L. RESULTS Between November 2017 and May 2018, 127 participants were randomly assigned 1:1 to CLC (n = 65) versus SAP (n = 62); 125 participants completed the study. CGM time below 3.9 mmol/L was 5.0% at baseline and 2.4% during follow-up in the CLC group vs. 4.7% and 4.0%, respectively, in the SAP group (mean difference −1.7% [95% CI −2.4, −1.0]; P &lt; 0.0001 for superiority). CGM time above 10 mmol/L was 40% at baseline and 34% during follow-up in the CLC group vs. 43% and 39%, respectively, in the SAP group (mean difference −3.0% [95% CI −6.1, 0.1]; P &lt; 0.0001 for noninferiority). One severe hypoglycemic event occurred in the CLC group, which was unrelated to the study device. CONCLUSIONS In meeting its coprimary end points, superiority of CLC over SAP in CGM-measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L, the study has demonstrated that mobile CLC is feasible and could offer certain usability advantages over embedded systems, provided the connectivity between system components is stable.
Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities
Folseraas, Trine , Roessler, Stéphanie , Kloor, Matthias , Endris, Volker , Buchhalter, Ivo , Stenzinger, Albrecht , Grzyb, Krzysztof , Grimsrud, Marit M. , Górnicka, Barbara , Seth, Erik von , Reynolds, Gary , Gotthardt, Daniel , Cheung, Angela , Verheij, Joanne , Arola, Johanna, Mäkisalo, Heikki, Eide, Tor J., Weidemann, Sören , Cheville, John C. , Ponsioen, Cyriel Y. , Bergquist, Annika , Manns, Michael P. , Färkkilâ, Martti , Vogel, Arndt , Group, International PSC Study, Boberg, Kirsten Muri , Schirmacher, Peter , Karlsen, Tom H. , Lazaridis, Konstantinos N. , Buchhalter, Ivo , Bergquist, Annika , Vogel, Arndt , Goeppert, Benjamin Frank , Volckmar, Anna‐Lena , Franke, André , Mehrabi, Arianeb , Mazza, Giuseppe Antonio , Hirschfield, Gideon M. , Milkiewicz, Piotr , Schramm, Christoph , Group, International PSC Study

Mayo Clinic

Hepatology | January 11, 2020 | Volume: 72 | Issue: 4 | Pages: 1253-1266

10.1002/hep.31110 | PMID 31925805 Get It

Background and Aims Lifetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is currently the leading cause of death in patients with PSC. To open new avenues for management, we aimed to delineate clinically relevant genomic and pathological features of a large panel of PSC‐associated BTC (PSC‐BTC). Approach and Results We analyzed formalin‐fixed, paraffin‐embedded tumor tissue from 186 patients with PSC‐BTC from 11 centers in eight countries with all anatomical locations included. We performed tumor DNA sequencing at 42 clinically relevant genetic loci to detect mutations, translocations, and copy number variations, along with histomorphological and immunohistochemical characterization. Regardless of the anatomical localization, PSC‐BTC exhibited a uniform molecular and histological characteristic similar to extrahepatic cholangiocarcinoma. We detected a high frequency of genomic alterations typical of extrahepatic cholangiocarcinoma, such as TP53 (35.5%), KRAS (28.0%), CDKN2A (14.5%), and SMAD4 (11.3%), as well as potentially druggable mutations (e.g., HER2/ERBB2). We found a high frequency of nontypical/nonductal histomorphological subtypes (55.2%) and of the usually rare BTC precursor lesion, intraductal papillary neoplasia (18.3%). Conclusions Genomic alterations in PSC‐BTC include a significant number of putative actionable therapeutic targets. Notably, PSC‐BTC shows a distinct extrahepatic morpho‐molecular phenotype, independent of the anatomical location of the tumor. These findings advance our understanding of PSC‐associated cholangiocarcinogenesis and provide strong incentives for clinical trials to test genome‐based personalized treatment strategies in PSC‐BTC.
Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017
Haagsma, Juanita A. , James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Lucchesi, Lydia R , Sylte, Dillon O , Adebayo, Oladimeji , Ahmadi, Alireza , Aichour, Miloud Taki Eddine, Alahdab, Fares , Al‐Raddadi, Rajaa , Alsharif, Ubai , Altirkawi, Khalid A , Anjomshoa, Mina, Appiah, Seth Christopher Yaw , Aremu, Olatunde , Arora, Amit , Assadi, Reza , Awasthi, Ashish , Quintanilla, Beatriz Paulina Ayala , Balalla, Shivanthi , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Behzadifar, Meysam, Bennett, Derrick , Bhaumik, Soumyadeep , Bhutta, Zulfiqar A , Bijani, Ali , Borges, Guilherme , Borschmann, Rohan , Bose, Dipan, Bražinová, Alexandra, Campuzano, Julio César , Cárdenas, Rosario , Carvalho, Félix , Castañeda-Orjuela, Carlos A , Catalá-López, Ferrán , Choi, Jee-Young Jasmine , Christopher, Devasahayam Jesudas , Crowe, Christopher S. , Dalal, Koustuv , Leo, Diego De, Neve, Jan‐Walter De , Deribe, Kebede , Dessie, Getenet , deVeber, Gabrielle , Dharmaratne, Samath Dhamminda , Doan, Linh Phuong , Driscoll, Tim , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Endries, Aman Yesuf , Faro, André , Fereshtehnejad, Seyed‐Mohammad , Fernandes, Eduarda , Fischer, Florian , Franklin, Richard C. , Fukumoto, Takeshi , Gezae, Kebede Embaye , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haghparast‐Bidgoli, Hassan , Haj‐Mirzaian, Arvin , Haj‐Mirzaian, Arya , Hamadeh, Randah R , Hassen, Hamid Yimam , Havmoeller, Rasmus, Henok, Andualem , Hı́jar, Martha, Hole, Michael K., Rad, Enayatollah Homaie , Hossain, Naznin , Hostiuc, Sorin , Igumbor, Ehimario , Irvani, Seyed Sina Naghibi , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jacobsen, Kathryn H. , Jahanmehr, Nader , Jakovljević, Mihajlo , Jha, Ravi Prakash , Shushtari, Zahra Jorjoran , Jozwiak, Jacek Jerzy , Jürisson, Mikk , Kalani, Rizwan, Kasaeian, Amir , Kelbore, Abraham Getachew , Kengne, André Pascal , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khan, Ejaz Ahmad , Kiadaliri, Ali , Kim, Yun Jin , Kısa, Adnan , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kumar, Manasi , Lalloo, Ratilal , Lam, Hilton Y. , Lami, Faris , Leasher, Janet L , Li, Shanshan , Linn, Shai , Lunevičius, Raimundas , Machado, Flávia Ribeiro , Razek, Hassan Magdy Abd El , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Malekzadeh, Reza, Malik, Manzoor Ahmad , Manda, Ana-Laura, Massenburg, Benjamin B. , Maulik, Pallab K , Meheretu, Hailemariam Abiy Alemu , Mehndiratta, Man Mohan, Mendoza, Walter, Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Moazen, Babak , Mezerji, Naser Mohammad Gholi, Mohammadibakhsh, Roghayeh , Mohammed, Shafiu , Molokhia, Mariam , Monasta, Lorenzo , Mondello, Stefania , Montero-Zamora, Pablo A. , Moodley, Yoshan , Moosazadeh, Mahmood , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Moschos, Marilita M. , Mousavi, Seyyed Meysam , Murthy, Srinivas , Musa, Kamarul Imran , Naik, Gurudatta , Nangia, Vinay, Nascimento, Bruno Ramos , Ndwandwe, Duduzile , Negoi, Ionuţ , Nguyen, Son Hoang , Nguyen, Long Hoang , Ningrum, Dina Nur Anggraini , Nirayo, Yirga Legesse, Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oladimeji, Olanrewaju , Olagunju, Andrew T , Olagunju, Tinuke O , Orpana, Heather , Otstavnov, Stanislav S , Mahesh, P A , Pakhalé, Smita , Park, Eun‐Kee , Pesudovs, Konrad , Polinder, Suzanne , Prakash, Swayam , Rafay, Anwar, Rafiei, Alireza , Rahimi, Siavash , Rahimi‐Movaghar, Vafa , Rahman, Muhammad Aziz , Kumar, Rajesh , Ramezanzadeh, Kiana, Rawaf, David Laith , Renzaho, André M. N. , Resnikoff, Serge , Roever, Leonardo , Sabde, Yogesh , Saddik, Basema , Salamati, Payman , Salimi, Yahya , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Santric-Milicevic, Milena M , Satpathy, Maheswar , Sawhney, Monika, Sawyer, Susan M. , Şaylan, Mete , Schwebel, David C. , Seedat, Soraya , Shaikh, Masood Ali, Shams-Beyranvand, Mehran , Shamsizadeh, Morteza , Sharif-Alhoseini, Mahdi , Sheikh, Aziz , Shigematsu, Mika, Shiri, Rahman , Shiue, Ivy , Silva, João Pedro , Sinha, Dhirendra Narain , Filho, Adauto Martins Soares , Soriano, Joan B. , Soshnikov, Sergey , Soyiri, Ireneous N , Starodubov, Vladimir I., Stein, Dan J. , Sufiyan, Mu’awiyyah Babale , Sunshine, Jacob E. , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Tessema, Gizachew Assefa , Thakur, Jarnail Singh , Car, Lorainne Tudor , Uzochukwu, Benjamin, Valdéz, Pascual , Varavikova, Elena A. , Vasconcelos, Ana Maria Nogales , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wijeratne, Tissa , Yadav, Priyanka , Yano, Yuichiro , Yenesew, Muluken Azage, Yisma, Engida , Younis, Mustafa Z , Zafar, Shamsa , Zaman, Sojib Bin , Zodpey, Sanjay , Hay, Simon I , Mokdad, Ali H. , Vos, Theo , Khubchandani, Jagdish , Padrón‐Monedero, Alicia , Wijeratne, T , Stein, Dan J , Islam, Sheikh Mohammed Shariful , Assadi, Reza , Rahman, Muhammad Aziz , Liu, Zichen, Roberts, Nicholas L S , Ahmed, Muktar Beshir , Alghnam, Suliman Abdullah , Aljunid, Syed Mohamed , Antonio, Carl Abelardo T. , Asayesh, Hamid , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Behzadifar, Meysam, Benjet, Corina L. , Benseñor, Isabela M. , Boufous, Soufiane , Carrero, Juan Jesús , Daryani, Ahmad , Daviţoiu, Dragoş Virgil , Degenhardt, Louisa J , Dolan, Kate A , Dubey, Manisha , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Filip, Irina , Gill, Tiffany K. , Gupta, Rahul, Hamidi, Samer , Haro, Josep María , Hassankhani, Hadi , Hendrie, Delia V. , Hı́jar, Martha , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jayatilleke, Achala Upendra , Jonas, Jost B , Kabir, Ali , Kalani, Rizwan, Khoja, Abdullah T , Kim, Young‐Eun , Kim, Daniel , Koyanagi, Ai , Lansingh, Van Charles , Malta, Déborah Carvalho , Mansournia, Mohammad Alì , Melese, Addisu Dagnaw , Meštrović, Tomislav , Moradi‐Lakeh, Maziar , Morrison, Shane D. , Najafi, Farid , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Olivares, Pedro Rufino , Patton, George , Phillips, Michael , Radfar, Amir , Rawaf, Salman , Rezaeian, Shahab , Ronfani, Luca , Roshandel, Gholamreza , Saxena, Sonia , Schneider, Ione Jayce Ceola , Sepanlou, Sadaf Ghajarieh , Shen, Jiabin , Singh, Jasvinder A. , Стародубов, В. И. , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tran, Khanh Bao , Tran, Bach Xuan , Uthman, Olalekan Abdulrahman , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Winkler, Andrea Sylvia , Azage, Muluken , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zhao, Yong , Lopez, Alan D , Olagunju, Andrew T , Alahdab, Fares

Mayo Clinic

Injury Prevention | January 9, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i12-i26

10.1136/injuryprev-2019-043296 | PMID 31915273 Get It

Background The epidemiological transition of non-communicable diseases replacing infectious diseases as the main contributors to disease burden has been well documented in global health literature. Less focus, however, has been given to the relationship between sociodemographic changes and injury. The aim of this study was to examine the association between disability-adjusted life years (DALYs) from injury for 195 countries and territories at different levels along the development spectrum between 1990 and 2017 based on the Global Burden of Disease (GBD) 2017 estimates. Methods Injury mortality was estimated using the GBD mortality database, corrections for garbage coding and CODEm—the cause of death ensemble modelling tool. Morbidity estimation was based on surveys and inpatient and outpatient data sets for 30 cause-of-injury with 47 nature-of-injury categories each. The Socio-demographic Index (SDI) is a composite indicator that includes lagged income per capita, average educational attainment over age 15 years and total fertility rate. Results For many causes of injury, age-standardised DALY rates declined with increasing SDI, although road injury, interpersonal violence and self-harm did not follow this pattern. Particularly for self-harm opposing patterns were observed in regions with similar SDI levels. For road injuries, this effect was less pronounced. Conclusions The overall global pattern is that of declining injury burden with increasing SDI. However, not all injuries follow this pattern, which suggests multiple underlying mechanisms influencing injury DALYs. There is a need for a detailed understanding of these patterns to help to inform national and global efforts to address injury-related health outcomes across the development spectrum.
Absence of VEGFR‐1/Flt‐1 signaling pathway in mice results in insensitivity to discogenic low back pain in an established disc injury mouse model
Qiu, Sujun , Shi, Changgui , Anbazhagan, Arivarasu Natarajan , Das, Vaskar, Arora, Vipin , Kc, Ranjan , O‐Sullivan, InSug , Wijnen, André J. van , Chintharlapalli, Sudhakar , Gott‐Velis, Gina, Richard, Ripper, Mwale, Fackson , Shibuya, Masabumi , Min, Shaoxiong , Im, Hee‐Jeong , van Wijnen, Andre J , Li, Xin

Mayo Clinic

Journal of Cellular Physiology | December 25, 2019 | Volume: 235 | Issue: 6 | Pages: 5305-5317

10.1002/jcp.29416 | PMID 31875985 Get It

Abstract Although degenerative disc disease (DDD) and related low back pain (LBP) are growing public health problems, the underlying disease mechanisms remain unclear. An increase in the vascular endothelial growth factor (VEGF) levels in DDD has been reported. This study aimed to examine the role of VEGF receptors (VEGFRs) in DDD, using a mouse model of DDD. Progressive DDD was induced by anterior stabbing of lumbar intervertebral discs in wild type (WT) and VEGFR‐1 tyrosine‐kinase deficient mice ( vegfr‐1 TK−/ − ). Pain assessments were performed weekly for 12 weeks. Histological and immunohistochemical assessments were made for discs, dorsal root ganglions, and spinal cord. Both vegfr‐1 TK − / − and WT mice presented with similar pathological changes in discs with an increased expression of inflammatory cytokines and matrix‐degrading enzymes. Despite the similar pathological patterns, vegfr‐1 TK − / − mice showed insensitivity to pain compared with WT mice. This insensitivity to discogenic pain was related to lower levels of pain factors in the discs and peripheral sensory neurons and lower spinal glial activation in the vegfr‐1 TK − / − mice than in the WT mice. Exogenous stimulation of bovine disc cells with VEGF increased inflammatory and cartilage degrading enzyme. Silencing vegfr‐1 by small‐interfering‐RNA decreased VEGF‐induced expression of pain markers, while silencing vegfr‐2 decreased VEGF‐induced expression of inflammatory and metabolic markers without changing pain markers. This suggests the involvement of VEGFR‐1 signaling specifically in pain transmission. Collectively, our results indicate that the VEGF signaling is involved in DDD. Particularly, VEGFR‐1 is critical for discogenic LBP transmission independent of the degree of disc pathology.